Evidence map›Paper›PMID 28994392›Full record

ArticleeLife2017

Building a better blood-brain barrier.

Courtney Lane-Donovan, Joachim Herz

Open access · goldAbstract readComment
In one paragraph

Article in eLife, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. The apolipoprotein receptor LRP3 compromises APP levels.Alzheimer's research & therapy · 2021
    Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Courtney Lane-DonovanDepartment of Neurology, University of California San Francisco, San Franciso, United States.ORCID 0000-0001-9504-8346
Joachim HerzDepartment of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, United States.ORCID 0000-0002-8506-3400
The University of Texas Southwestern Medical Center · USUniversity of California, San Francisco · US

Funding

Metabolism of the VLDL receptor and ApoE receptor 2R37HL063762 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI HERZ, JOACHIM J · 2010 to 2019
$4.0M
Physiology and Pathophysiology of Apolipoprotein E receptor-2 splicing in Alzheimer's diseaseRF1AG053391 · NIA · UT SOUTHWESTERN MEDICAL CENTER · PI HERZ, JOACHIM J · 2016 to 2020
$2.4M
Molecular Basis of Synaptic Suppression by ApoER01NS093382 · NINDS · UT SOUTHWESTERN MEDICAL CENTER · PI HERZ, JOACHIM J · 2016 to 2020
$2.0M
NHLBI NIH HHS R37 HL063762NIA NIH HHS RF1 AG053391NINDS NIH HHS R01 NS093382
6 · The paper itself

Abstract

A new three-dimensional model of the blood-brain barrier can be used to study processes that are involved in neurodegenerative diseases.

Indexed as

Blood-Brain BarrierNeurodegenerative DiseasesApolipoproteins EBiological TransportHumansLipoproteins, HDLApolipoproteins ELipoproteins, HDLAlzheimer diseasecerebrovasculaturehumanhuman biologylipoproteinmedicineneurosciencetissue engineering

Identifiers

PMID28994392
PMCPMC5634780
OpenAlexW2761280123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.